Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
140actual
Sites
50
Countries
Belgium, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-29 | actual | When the study began enrolling |
| Primary completion | 2023-08-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2019-11-08 | actual | When this record first appeared on the registry |
| Results posted | 2025-01-14 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Eosinophilic Granulomatous Vasculitis
Interventions
- Biological: Benralizumab
- Biological: Mepolizumab
- Biological: Placebo to Mepolizumab
- Biological: Placebo to Benralizumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Subjects Who Achieved Main Remission at Both Weeks 36 and 48
measured Week 36 and Week 48
Supportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 48
measured Week 36 and Week 48
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-03-06 · 1.5 MB · Prot_016.pdf
Statistical Analysis Planposted 2023-07-04 · 1.1 MB · SAP_017.pdf
Publications
- PMID 38393328 — linked by the registry
- PMID 33164993 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed